Evaluating an Interactive Digital Toolkit for Women's PrEP Implementation

NCT ID: NCT07292584

Last Updated: 2025-12-18

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

NA

Total Enrollment

125 participants

Study Classification

INTERVENTIONAL

Study Start Date

2026-03-31

Study Completion Date

2027-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this study is to test if a Digital PrEP Toolkit helps cisgender women learn about and access PrEP in Alabama and Mississippi. PrEP is a medication that prevents HIV infection. The main questions it aims to answer are: Can participants complete the Digital PrEP Toolkit in under 10 minutes? Do participants find the Digital PrEP Toolkit useful and easy to use? Does the Digital PrEP Toolkit increase the number of women who start taking PrEP?

Investigators will work with up to 125 women at 3 HIV and STI clinics in Alabama and Mississippi.

Participants will use the Digital PrEP Toolkit on a tablet at the clinic. They will answer questions about their HIV knowledge before and after using the Toolkit. Participants will then discuss PrEP options with a healthcare staff member and decide if they want to start PrEP. Participants will answer follow-up questions at 3 months. Investigators will also review participants' medical records at 6 months to see if they started PrEP and are still taking it.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Cisgender women in the rural southeastern United States face substantial HIV risk. Despite this, pre-exposure prophylaxis (PrEP) use among women remains alarmingly low. PrEP is a medication that prevents HIV infection. Barriers to PrEP use among women include limited PrEP awareness and knowledge, low HIV risk perception, challenging client-provider conversations about sexual health, and structural challenges like transportation difficulties and time constraints.

This study will test an Interactive Digital PrEP Toolkit that includes HIV prevention education tailored to women in the Southeast, information about different PrEP medication options (i.e., daily oral pills, monthly injections, and twice-yearly injections), questions to help identify HIV prevention preferences, and testimonials from women using PrEP. The study will enroll up to 125 cisgender women at 3 HIV and STI clinic locations in Alabama and Mississippi over approximately 12 months.

Study Outcomes:

Primary outcomes include feasibility, acceptability, and preliminary efficacy. Feasibility will be measured by Toolkit completion rate, average time to complete the Toolkit, proportion of participants who initiate PrEP, and changes in HIV and PrEP knowledge. Acceptability will be measured through participant satisfaction surveys assessing how valuable and easy to use participants find the Digital PrEP Toolkit. Preliminary efficacy will be measured by comparing clinic-level PrEP uptake rates during up to 12 months preceding the study start to those during the approximately 12-month study period among all eligible female clients seen at participating clinics.

Secondary outcomes will include documentation of participants' sexual health priorities, HIV prevention preferences, and PrEP modality choices across the clinic sites. Investigators will also assess retention in PrEP care at 6 months post-enrollment.

Study Procedures:

Participants will complete a 30-minute enrollment visit at the clinic. They will provide informed consent, complete baseline assessments on HIV and PrEP knowledge, health-related questions, and demographics, and use the Interactive Digital PrEP Toolkit on a tablet. After completing the Toolkit, participants will receive a Personalized HIV Prevention Summary and meet with a healthcare staff member to discuss PrEP. Participants interested in PrEP will be scheduled for a PrEP clinic appointment.

At 3 months, Research staff will contact participants by phone for a follow-up interview about HIV and PrEP knowledge, sexual health, PrEP uptake and adherence, and experiences with the Toolkit. Research staff will also review medical records at 3 months for PrEP prescriptions.

At 6 months, research staff will review medical records for continued PrEP prescriptions. Participants will not be contacted at 6 months.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

HIV Prevention HIV Risk Sexual and Reproductive Health

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

PrEP HIV prevention cisgender women Digital Health Digital Intervention Health Education Decision Support Tool Alabama Mississippi Southeast United States

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Implementation of interactive digital PrEP toolkit for increased PrEP uptake

The goal of the intervention is to strengthen the PrEP care continuum by developing and testing an interactive digital PrEP toolkit designed to improve PrEP awareness, screening, engagement, retention, adherence, and persistence among individuals at increased risk for HIV seroconversion. Specifically, the intervention aims to reduce racial and gender disparities in PrEP uptake and use.

Group Type EXPERIMENTAL

Interactive Digital PrEP Toolkit

Intervention Type BEHAVIORAL

Evaluation of an Interactive Digital PrEP Toolkit for women in AL and MS

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Interactive Digital PrEP Toolkit

Evaluation of an Interactive Digital PrEP Toolkit for women in AL and MS

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* HIV-negative
* Cisgender women
* 18 years or older
* English-speaking
* Report sexual activity in the last six months or anticipate sexual activity in the next six months.

Exclusion Criteria

* Younger than 18 years of age
* Do not identify as female and/or were not biologically assigned female at birth
* Living with HIV
* Report no sexual activity in the past six months and no anticipated sexual activity in the next six months
* Unable or unwilling to provide informed consent
Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Massachusetts General Hospital

OTHER

Sponsor Role collaborator

University of Alabama at Birmingham

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Mirjam-Colette Kempf

University Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Mirjam-Colette Kempf, PhD, MPH

Role: PRINCIPAL_INVESTIGATOR

University of Alabama at Birmingham

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Alabama at Birmingham

Birmingham, Alabama, United States

Site Status

Five Horizons Health Services

Montgomery, Alabama, United States

Site Status

Five Horizons Health Services

Tuscaloosa, Alabama, United States

Site Status

Five Horizons Health Services

Starkville, Mississippi, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Mirjam-Colette Kempf, PhD, MPH

Role: CONTACT

Phone: 205-934-9333

Email: [email protected]

Victoria McDonald, MPH

Role: CONTACT

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Victoria McDonald, MPH

Role: primary

Director of Research and Grant Administration

Role: primary

Director of Research and Grant Administration

Role: primary

Director of Research and Grant Administration

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

000548592

Identifier Type: OTHER_GRANT

Identifier Source: secondary_id

IRB-300015561

Identifier Type: -

Identifier Source: org_study_id